Weighing PSA benefits and harms, the European Association of Urology (EAU) [6] recommended in 2017 that doctors offer an individualized, early-detection strategy to informed patients with good performance status and life expectancy of at least 10–15 years if they have elevated risk of PCa (men > 50 years or 45 years if they are African American or have a PCa family history). Here, KLK3 is linked to posterior cortical atrophy.